Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05660538 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
NCT05660538 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 194 participants.
The verdict
NCT05660538, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.
Interventions
- DRUG Suzetrigine
- DRUG Pregabalin
- DRUG Placebo (matched to pregabalin)
- DRUG Placebo (matched to SUZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2023-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05660538
The ClinicalTrials.gov registry entry for NCT05660538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Suzetrigine is the first listed.
NCT05660538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05660538 about?
NCT05660538 is a clinical study titled "Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)". The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.
What is the current status of trial NCT05660538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2022-12-20. Estimated completion is 2023-10-25.
What interventions are being tested in trial NCT05660538?
The interventions under investigation include: Suzetrigine (DRUG), Pregabalin (DRUG), Placebo (matched to pregabalin) (DRUG), Placebo (matched to SUZ) (DRUG).
Who is sponsoring clinical trial NCT05660538?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.